Telomir reported preclinical in vitro data showing that Telomir-Zn inhibited growth in three osteosarcoma cell lines of human and canine origin, with dose-dependent activity at comparable low concentrations. The compound acts on intracellular iron and copper handling, depleting labile iron pools and inhibiting iron-dependent histone demethylases to reverse cancer-associated epigenetic silencing. Findings remain at the cell-culture stage, with in vivo and clinical testing required before any conclusion on safety or efficacy.
Key Points
- Dose-dependent growth inhibition across HOS, D17 and Abrams cell lines
- Mechanism targets labile iron pools and iron-dependent histone demethylases
- Canine osteosarcoma in vivo study under discussion with Ohio State
Longevity Analysis
Transition metal handling sits at the intersection of energy metabolism, oxidative burden and epigenetic regulation, and its dysregulation accumulates with age. Targeting labile iron and copper pools to restore silenced gene expression treats metal excess as removable interference rather than an inevitable feature of aging tissue, a logic that extends beyond oncology to how cells maintain repair capacity and immune surveillance over decades. Naturally occurring canine osteosarcoma offers a comparative model with intact physiology and shared environmental exposures, which strengthens the translational value of any subsequent in vivo signal.
Original published by LT Wire.